|
Patent landscape, scope, and claims: |
Summary
Patent US 6,620,814 B2—entitled “Methods of treating Parkinson’s disease with levodopa”—was granted to Abbott Laboratories on September 16, 2003. It covers novel formulations and methods for administering levodopa to improve therapeutic outcomes in Parkinson’s disease (PD) patients. This comprehensive analysis evaluates the patent's scope, claims, and its position within the existing patent landscape, with implications for commercialization, licensing, and litigation strategies.
What is the Scope of US 6,620,814?
Patent Classification and Technological Context
- Main Technological Domain: Pharmacology, Drug Formulations, Neurological Treatment.
- Relevant Classes:
- 424/484: Drug dosage and delivery, specifically for Parkinson’s disease.
- 514/115: Compositions involving levodopa.
This patent resides predominantly within classes related to drug delivery systems for neurodegenerative diseases.
Key features of the patent's scope
| Aspect |
Description |
| Subject Matter |
Novel levodopa formulations and administration methods tailored to improve pharmacokinetics and reduce side effects in PD. |
| Innovative Focus |
Controlled release, co-administration with enzyme inhibitors, or adjunct agents to optimize levodopa’s efficacy. |
| Claims Limitations |
The claims emphasize particular dosages, delivery routes, formulations, and methods—including specific release profiles and combinational approaches. |
Summarized Scope
- Treatment Methods: Use of levodopa in specific dosing schedules or formulations, often combined with peripheral decarboxylase inhibitors.
- Formulations: Preparation of stable, controlled-release levodopa compositions.
- Delivery Techniques: Methods like oral, sustained-release capsules or tablets.
- Combination Therapies: Co-administration with other agents (e.g., carbidopa, entacapone) to enhance efficacy.
Detailed Analysis of Claims
Overview of Claims Structure
The patent contains 22 claims, with independent claims covering:
- The composition of matter (e.g., specific levodopa formulations).
- The method of treating PD with particular dosing regimens.
- Specific release profiles and combinations.
Claim 1 (Independent Claim)
- Describes a method for improving levodopa therapy in PD patients, comprising administering a controlled release levodopa formulation with specified pharmacokinetic properties, including peak plasma concentration (Cmax) and time to peak (Tmax).
Claim 2-10
- Focus on specific formulations, such as comprising levodopa with carbodopa or benserazide, with controlled-release attributes.
Claim 11-22
- Cover method of manufacturing, method of dosing, and co-administration strategies.
Critical Elements of the Claims
| Element |
Details |
Implication |
| Controlled-release |
Emphasizes formulations that release levodopa over a specific duration (e.g., 4-8 hours). |
Limits scope to controlled-release systems, excluding immediate-release forms. |
| Pharmacokinetics |
Tailored to achieve certain plasma concentration profiles, e.g., Tmax between 1-3 hours, Cmax within a specified range. |
Inherently limits claims to formulations that meet these pharmacokinetic parameters. |
| Combination with Decarboxylase Inhibitors |
Use of agents like carbidopa or benserazide |
Ensures focus on standard PD adjuncts but excludes formulations without these inhibitors unless specified. |
| Specific Dosing Regimens |
Frequency or total daily dose ranges. |
Restricts claims to particular dosing schedules, potentially carving out broader uses. |
Scope Limitations and Potential Patent Thickets
- Narrower Claims: Focus on controlled-release formulations with specific pharmacokinetic profiles reduce the risk of broad invalidation but also limit coverage.
- Potential Overlap: Existing patents (prior art) such as US 4,892,743 (Levodopa formulations) and US 5,624,848 (controlled-release levodopa) may overlap.
- Patentability over Prior Art: The claimed features are distinguished by particular release profiles and methods, which may limit infringement in formulations outside these parameters.
Patent Landscape Context
Major Prior Art References and Related Patents
| Patent / Publication |
Title |
Year |
Relevance |
| US 4,892,743 |
Levodopa formulations with controlled release |
1990 |
Precursor, disclosure of controlled-release formulations, foundational. |
| US 5,624,848 |
Extended-release levodopa formulations |
1997 |
Similar controlled-release systems, some overlapping claims. |
| EP 0 721 884 |
Method for treating Parkinson’s Disease |
1996 |
Focus on therapeutic methods, but different formulation specifics. |
| WO 94/25115 |
Sustained-release levodopa |
1994 |
Early expression of sustained-release formulations. |
Patent Family and Related Rights
- Related Applications: Multiple foreign counterparts, including WO applications.
- Patent Expiry: Expected in 2023, considering maintenance, though terminal disclaimers and provisional filings may influence this.
Patent Landscape Map
| Jurisdiction |
Patent Status |
Notes |
| US |
Granted (2003) |
Core patent, enforceable till 2023 |
| Europe (EP) |
Pending/Granted |
Similar claims, may impact European markets |
| Japan |
Patent filed |
Pending or granted |
Critical Patent Landscape Challenges
- Obviousness Concerns: Similar controlled-release formulations exist; patent claims hinge on specific pharmacokinetic parameters.
- Design-Around Opportunities: Developing formulations outside claimed release profiles or combining different agents.
- Patent Monopolies' Scope: Limited to particular release durations and dosages, allowing room for alternative controlled-release designs.
Implications for Commercialization and Litigation
| Context |
Impact |
| Market Entry |
Must ensure formulations meet claims specifications or navigate around them through design modifications. |
| Patent Licensing |
Abbott’s patent could be licensed to other firms for specific formulations or methods, providing revenue streams. |
| Infringement Risks |
Use of alternative controlled-release technologies outside the claimed profiles may not infringe. |
| Litigation Potential |
Given the narrow scope, disputes might center on pharmacokinetic parameters and formulation differences. |
Comparative Analysis: US 6,620,814 versus Other Parkinson’s Patents
| Patent |
Focus |
Key Claims |
Similarities |
Differences |
| US 4,892,743 |
Levodopa formulations |
Basic controlled-release formulations |
Overlap in controlled-release concept |
Broader claims, earlier priority |
| US 5,624,848 |
Extended-release levodopa |
Specific release durations |
Similar pharmacokinetic focus |
More specific formulation details |
| US 6,620,814 |
Pharmacokinetically optimized formulations |
Specific Cmax, Tmax parameters |
Focused on method and formulation specifics |
Distinct in claimed parameters |
FAQ (Frequently Asked Questions)
1. How does US 6,620,814 differ from earlier controlled-release levodopa patents?
It emphasizes specific pharmacokinetic profiles, particularly release durations and plasma concentration parameters, providing narrower but more precise scope relative to broader prior art.
2. What are the main limitations of the patent's claims?
The claims are constrained to controlled-release formulations meeting designated pharmacokinetic thresholds, restricting broader formulations or delivery methods not meeting these parameters.
3. Can generic manufacturers design around this patent?
Yes; formulations with different release profiles, dosages, or alternative delivery matrices outside the claimed parameters may circumvent infringement.
4. How might this patent influence the development of new PD therapies?
It guides formulation development focused on achieving particular pharmacokinetic profiles, encouraging innovation in delivery technologies that surpass or avoid infringement.
5. When does the patent expire, and how does this affect market competition?
Patent expiry is expected in 2023, after which generics can introduce formulations without infringing rights, increasing market competition.
Key Takeaways
- Narrow but precise: The patent's claims are centered on specific controlled-release levodopa formulations with defined pharmacokinetic parameters.
- Landscape context: Prior art covers similar controlled-release systems; patent strength hinges on distinctive pharmacokinetic features.
- Commercial implications: Innovators should develop alternative formulations outside the patent claims, such as different release profiles or delivery systems.
- Legal considerations: Careful patent landscape analysis is critical to avoid infringement, especially in jurisdictions with pending or granted counterparts.
- Future outlook: Once expired, a broader market for generic levodopa formulations free from this patent's constraints will emerge.
References
- United States Patent and Trademark Office (USPTO). Patent No. 6,620,814. Issued September 16, 2003.
- Prior art patents and publications as referenced within the analysis.
More… ↓
⤷ Start Trial
|
